These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38332944)

  • 1. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.
    Angelico F
    Drugs Context; 2024; 13():. PubMed ID: 38332944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report.
    Chantarojanasiri T
    Drugs Context; 2023; 12():. PubMed ID: 37077770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report.
    Hashem A
    Drugs Context; 2023; 12():. PubMed ID: 37313039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37342459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silymarin in the management of liver enzyme activity in steatohepatitis: a case report.
    Torre A
    Drugs Context; 2023; 12():. PubMed ID: 37077767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review.
    Tighe SP; Akhtar D; Iqbal U; Ahmed A
    J Clin Transl Hepatol; 2020 Dec; 8(4):454-458. PubMed ID: 33447529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37313040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations.
    Gillessen A; Angelico F; Chen J; Lu L; Lucena MI; Fu Q; Xie Q; Andrade RJ; Xie W; Xu X; Yu Y; Mao YM; Nan Y
    Gastro Hep Adv; 2022; 1(5):882-893. PubMed ID: 39131840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.
    Jaffar HM; Al-Asmari F; Khan FA; Rahim MA; Zongo E
    Food Sci Nutr; 2024 May; 12(5):3097-3111. PubMed ID: 38726410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37205125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review.
    Dhande D; Dhok A; Anjankar A; Nagpure S
    Cureus; 2024 Aug; 16(8):e67083. PubMed ID: 39286715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review and expert opinion on MAFLD, oxidative stress and multifunctional management.
    Angelico F; Alcantara-Payawal D; Rani RA; Mustafa N; Thongtang N; Chaiteerakij R; Bunchorntavakul C; Sukonthasarn A
    Drugs Context; 2024; 13():. PubMed ID: 38264403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
    Federico A; Dallio M; Loguercio C
    Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of silymarin in the treatment of liver diseases.
    Saller R; Meier R; Brignoli R
    Drugs; 2001; 61(14):2035-63. PubMed ID: 11735632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Silymarin in the treatment of chronic liver diseases: past and future].
    Fehér J; Lengyel G
    Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.
    Pradhan SC; Girish C
    Indian J Med Res; 2006 Nov; 124(5):491-504. PubMed ID: 17213517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytotherapy and NAFLD--from goals and challenges to clinical practice.
    Milosević N; Milanović M; Abenavoli L; Milić N
    Rev Recent Clin Trials; 2014; 9(3):195-203. PubMed ID: 25514914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.
    Lee HA; Chang Y; Sung PS; Yoon EL; Lee HW; Yoo JJ; Lee YS; An J; Song DS; Cho YY; Kim SU; Kim YJ
    Clin Mol Hepatol; 2022 Jul; 28(3):425-472. PubMed ID: 35850495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silybin and the liver: from basic research to clinical practice.
    Loguercio C; Festi D
    World J Gastroenterol; 2011 May; 17(18):2288-301. PubMed ID: 21633595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.